MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company's parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). The publication, titled "MBX 2109, a Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial", was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be accessed here.
MBX生命科学公司（纳斯达克股票代码：MBX）是一家临床阶段生物制药公司，专注于发现和开发用于治疗内分泌和代谢疾病的新型精准肽治疗药物。今天宣布，《临床内分泌与代谢杂志》（JCEM）发表了一篇同行评议文章，重点介绍了MBX 2109阶段1研究的结果。MBX 2109是公司正在开发用于治疗甲状旁腺功能减退症（HP）的甲状旁素（PTH）肽前药。该文章名为《MBX 2109，一种每周一次的甲状旁腺激素替代治疗前药：阶段1，首次进行人体随机试验》，可在此处阅读。
